Loading...
XETR
DMP
Market cap2.26bUSD
Apr 17, Last price  
36.50EUR
1D
-1.88%
1Q
-9.54%
IPO
35.59%
Name

Dermapharm Holding SE

Chart & Performance

D1W1MN
P/E
17.27
P/S
1.66
EPS
2.11
Div Yield, %
4.82%
Shrs. gr., 5y
0.05%
Rev. gr., 5y
11.00%
Revenues
1.18b
+4.00%
391,340,000384,843,000444,478,000467,117,000572,424,000700,879,000793,829,000942,912,0001,024,776,0001,135,351,0001,180,766,000
Net income
114m
+82.44%
-61,00012,701,00016,824,00077,744,00075,323,00077,196,00085,826,000209,583,000134,236,00062,368,000113,787,000
CFO
201m
-8.22%
54,256,00040,377,00076,778,00086,736,000159,128,000100,614,000131,098,000250,368,000288,533,000219,422,000201,378,000
Dividend
Jun 27, 20250.9 EUR/sh
Earnings
May 13, 2025

Profile

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
IPO date
Feb 09, 2018
Employees
3,404
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,180,766
4.00%
1,135,351
10.79%
1,024,776
8.68%
Cost of revenue
513,607
522,102
443,869
Unusual Expense (Income)
NOPBT
667,159
613,249
580,907
NOPBT Margin
56.50%
54.01%
56.69%
Operating Taxes
60,268
45,462
83,680
Tax Rate
9.03%
7.41%
14.41%
NOPAT
606,891
567,787
497,227
Net income
113,787
82.44%
62,368
-53.54%
134,236
-35.95%
Dividends
(47,379)
(56,532)
(116,833)
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
89,935
116,430
4,887
Long-term debt
907,147
982,207
524,295
Deferred revenue
11,337
9,204
Other long-term liabilities
132,092
268,325
91,269
Net debt
793,091
864,568
302,410
Cash flow
Cash from operating activities
201,378
219,422
288,533
CAPEX
(38,237)
(41,541)
(39,014)
Cash from investing activities
(29,614)
(415,432)
(99,008)
Cash from financing activities
(209,169)
204,538
(199,768)
FCF
595,115
347,661
531,285
Balance
Cash
121,706
159,542
161,358
Long term investments
82,285
74,527
65,414
Excess cash
144,953
177,301
175,533
Stockholders' equity
490,904
444,258
431,702
Invested Capital
1,586,383
1,705,313
863,131
ROIC
36.87%
44.21%
55.10%
ROCE
36.20%
32.57%
53.33%
EV
Common stock shares outstanding
53,962
53,840
53,840
Price
Market cap
EV
EBITDA
753,944
717,836
675,816
EV/EBITDA
Interest
58,408
54,968
12,338
Interest/NOPBT
8.75%
8.96%
2.12%